AI hit-to-lead optimization for drug discovery

The Challenge

A mid-sized pharmaceutical company sought to accelerate the hit-to-lead optimization process by identifying the most promising chemical structures with high activity while ensuring synthetic feasibility.

Our Approach

We applied a cheminformatics-driven strategy, leveraging clustering and Maximum Common Substructure (MCS) search to refine the molecular representation model. Using our state-of-the-art COPTIC framework, we employed reinforcement learning to generate optimized compound structures with desired properties.

Results

  • Generated 6,656 compounds, of which 5,857 were unique
  • 2,622 compounds exhibited an EC50 <10nM, indicating high potency
  • Developed a predictive model with >90% accuracy
  • Ensured synthetic accessibility and docking feasibility of the proposed compounds

By integrating AI-driven cheminformatics, we enhanced hit-to-lead workflows, significantly reducing the time needed for molecular optimization.

You might be also interested in:

BIO Convention 2025
BIO International Convention 2025 – New Standards in Collaboration, Innovation, and the Integration of AI in Biotechnology
Biologics 2.0 – From monoclonal antibodies to multispecific therapeutics
Computer Vision Meets Life Sciences: Inside the CVPR 2025 Workshop Co-Organized by Ardigen
High-performance computing servers powering biomedical data pipelines and drug discovery.
Beyond the Petabytes: What It Really Takes to Power the Next Leap in Drug Discovery

Contact

Ready to transform drug discovery?

Discover how one of the top AI CROs in the world, can be your trusted partner in revolutionizing drug discovery through AI.

Contact us today to learn more about our tailored solutions for empowering your drug development journey.

Send us a message and we will contact you back within 48 hours.

Newsletter

Become an insider

Be the first to know about Ardigen’s latest news and get access to our publications, webinars and more!